-
公开(公告)号：US08697079B2
公开(公告)日：2014-04-15
申请号：US13372557
申请日：2012-02-14
申请人： Manuel L. Penichet , Birgit C. Schultes , Christopher F. Nicodemus , Tracy R. Daniels , Gustavo Helguera , Jose A. Rodriguez
发明人： Manuel L. Penichet , Birgit C. Schultes , Christopher F. Nicodemus , Tracy R. Daniels , Gustavo Helguera , Jose A. Rodriguez
IPC分类号： A61K39/395
CPC分类号： C07K16/3069 , C07K2317/24
摘要： The present invention provides monoclonal IgE antibodies comprising Fc epsilon (ε) constant regions and variable regions comprising at least one antigen binding region specific for binding a single epitope of a circulating, tumor-associated antigen (TAA) that is not a cell surface antigen wherein the epitope of the targeted antigen is not highly repetitive or is a non-repetitive epitope. The IgE antibodies of the invention are useful in the treatment of cancer associated with the tumor antigen. In one embodiment the TAA is prostate-specific antigen (PSA).
摘要翻译： 本发明提供包含Fcε（恒定）恒定区和可变区的单克隆IgE抗体，所述可变区包含至少一个特异性结合不是细胞表面抗原的循环，肿瘤相关抗原（TAA）的单个表位的抗原结合区 其中靶向抗原的表位不是高度重复的或是不重复的表位。 本发明的IgE抗体可用于治疗与肿瘤抗原相关的癌症。 在一个实施方案中，TAA是前列腺特异性抗原（PSA）。
-
公开(公告)号：US08038994B2
公开(公告)日：2011-10-18
申请号：US10831886
申请日：2004-04-26
IPC分类号： A61K39/395
CPC分类号： C07K16/3069 , A61K39/39558 , A61K2039/505 , A61K2300/00
摘要： Disclosed are methods for treating cancer comprising administering a xenotypic antibody and a chemotherapeutic drug to a patient suffering from cancer. Also disclosed is a method for inducing a host immune response in a patient against a multi-epitopic in vivo tumor antigen present in the host serum, which antigen does not elicit an effective host immune response, comprising administering to the patient a chemotherapeutic drug and a composition comprising a binding agent that specifically binds to a first epitope on the antigen and allowing the binding agent to form a binding agent/antigen pair, wherein an effective host immune response is elicited against a second epitope on the antigen.
摘要翻译： 公开了用于治疗癌症的方法，包括向患有癌症的患者施用异型抗体和化学治疗药物。 还公开了一种诱导患者中存在于宿主血清中的多表位体内肿瘤抗原的宿主免疫应答的方法，该抗原不引起有效的宿主免疫应答，其包括向患者施用化学治疗药物和 组合物，其包含特异性结合抗原上的第一表位并使结合剂形成结合剂/抗原对的结合剂，其中针对抗原上的第二表位引起有效的宿主免疫应答。
-
公开(公告)号：US20080311127A1
公开(公告)日：2008-12-18
申请号：US11981713
申请日：2007-10-31
IPC分类号： A61K39/395 , A61P35/00
CPC分类号： A61K39/39558 , A61K39/00 , A61K2039/505 , C07K16/303 , C07K16/3069 , C07K16/4266 , C07K2317/55 , C07K2317/622 , C07K2317/732 , C07K2317/734 , C07K2317/76 , A61K38/177 , A61K2300/00
摘要： Disclosed are methods for treating cancer comprising administering a xenotypic antibody and a chemotherapeutic drug to a patient suffering from cancer. Also disclosed is a method for inducing a host immune response in a patient against a multi-epitopic in vivo tumor antigen present in the host serum, which antigen does not elicit an effective host immune response, comprising administering to the patient a chemotherapeutic drug and a composition comprising a binding agent that specifically binds to a first epitope on the antigen and allowing the binding agent to form a binding agent/antigen pair, wherein an effective host immune response is elicited against a second epitope on the antigen.
摘要翻译： 公开了用于治疗癌症的方法，包括向患有癌症的患者施用异型抗体和化学治疗药物。 还公开了一种诱导患者中存在于宿主血清中的多表位体内肿瘤抗原的宿主免疫应答的方法，该抗原不引起有效的宿主免疫应答，包括向患者施用化学治疗药物和 组合物，其包含特异性结合抗原上的第一表位并使结合剂形成结合剂/抗原对的结合剂，其中针对抗原上的第二表位引起有效的宿主免疫应答。
-
4.发明授权Methods for improving the bioactivity of therapeutic IgE antibodies for the treatment of disease 有权改善治疗性IgE抗体生物活性以治疗疾病的方法公开(公告)号：US08945566B2
公开(公告)日：2015-02-03
申请号：US13456492
申请日：2012-04-26
IPC分类号： A61K39/395 , A61K39/00
CPC分类号： A61K39/0011 , A61K39/395 , A61K2039/555 , C07K2317/52 , Y10S424/805 , Y10S530/862 , A61K2300/00
摘要： The invention provides a method for increasing the bioactivity (e.g. the biosafety and efficacy) of a therapeutic IgE antibody of the invention in the treatment of a patient. Methods of the invention include: i) administering to the patient a therapeutic IgE antibody in combination with at least one bioactivity-enhancing agent, ii) strategic treatment regimens and protocols for the dosing and administration of a therapeutic IgE antibody of the invention, and iii) the use of a therapeutic IgE antibody having a variable region comprising at least one antigen binding region specific for binding an epitope of an antigen wherein the epitope is not highly repetitive or is non-repetitive.
摘要翻译： 本发明提供了一种用于增加本发明的治疗性IgE抗体在患者治疗中的生物活性（例如生物安全性和功效）的方法。 本发明的方法包括：i）向患者施用治疗性IgE抗体与至少一种生物活性增强剂的组合，ii）用于给药和施用本发明的治疗性IgE抗体的策略治疗方案和方案，以及iii ）使用治疗性IgE抗体，其具有包含至少一个特异性结合抗原表位的抗原结合区的可变区，其中所述表位不是高度重复的或不重复的。
-
5.发明申请METHODS FOR IMPROVING THE BIOACTIVITY OF THERAPEUTIC IgE ANTIBODIES FOR THE TREATMENT OF DISEASE 审中-公开改善治疗性疾病的治疗性IgE抗体的生物活性的方法公开(公告)号：US20110256124A1
公开(公告)日：2011-10-20
申请号：US12900251
申请日：2010-10-07
IPC分类号： A61K39/395 , A61P35/00 , A61P37/06 , A61P37/04
CPC分类号： A61K39/0011 , A61K39/395 , A61K2039/555 , C07K2317/52 , Y10S424/805 , Y10S530/862 , A61K2300/00
摘要： The invention provides a method for increasing the bioactivity (e.g. the biosafety and efficacy) of a therapeutic IgE antibody of the invention in the treatment of a patient. Methods of the invention include: i) administering to the patient a therapeutic IgE antibody in combination with at least one bioactivity-enhancing agent, ii) strategic treatment regimens and protocols for the dosing and administration of a therapeutic IgE antibody of the invention, and iii) the use of a therapeutic IgE antibody having a variable region comprising at least one antigen binding region specific for binding an epitope of an antigen wherein the epitope is not highly repetitive or is non-repetitive.
摘要翻译： 本发明提供了一种用于增加本发明的治疗性IgE抗体在患者治疗中的生物活性（例如生物安全性和功效）的方法。 本发明的方法包括：i）向患者施用治疗性IgE抗体与至少一种生物活性增强剂的组合，ii）用于给药和施用本发明的治疗性IgE抗体的策略治疗方案和方案，以及iii ）使用治疗性IgE抗体，其具有包含至少一个特异性结合抗原表位的抗原结合区的可变区，其中所述表位不是高度重复的或不重复的。
-
6.发明申请METHODS FOR IMPROVING THE BIOACTIVITY OF THERAPEUTIC IgE ANTIBODIES FOR THE TREATMENT OF DISEASE 有权改善治疗性疾病的治疗性IgE抗体的生物活性的方法公开(公告)号：US20130058920A1
公开(公告)日：2013-03-07
申请号：US13456492
申请日：2012-04-26
IPC分类号： A61K39/395 , A61P35/00 , A61P37/02 , A61P37/08
CPC分类号： A61K39/0011 , A61K39/395 , A61K2039/555 , C07K2317/52 , Y10S424/805 , Y10S530/862 , A61K2300/00
摘要： The invention provides a method for increasing the bioactivity (e.g. the biosafety and efficacy) of a therapeutic IgE antibody of the invention in the treatment of a patient. Methods of the invention include: i) administering to the patient a therapeutic IgE antibody in combination with at least one bioactivity-enhancing agent, ii) strategic treatment regimens and protocols for the dosing and administration of a therapeutic IgE antibody of the invention, and iii) the use of a therapeutic IgE antibody having a variable region comprising at least one antigen binding region specific for binding an epitope of an antigen wherein the epitope is not highly repetitive or is non-repetitive.
摘要翻译： 本发明提供了一种用于增加本发明的治疗性IgE抗体在患者治疗中的生物活性（例如生物安全性和功效）的方法。 本发明的方法包括：i）向患者施用治疗性IgE抗体与至少一种生物活性增强剂的组合，ii）用于给药和施用本发明的治疗性IgE抗体的策略治疗方案和方案，以及iii ）使用治疗性IgE抗体，其具有包含至少一个特异性结合抗原表位的抗原结合区的可变区，其中所述表位不是高度重复的或不重复的。
-
7.发明授权Polynucleotides that encode the human proteoglycan peptide core of the effector cells of the immune response 失效编码免疫应答的效应细胞的人蛋白聚糖肽核心的多核苷酸
公开(公告)号：US5317085A
公开(公告)日：1994-05-31
申请号：US909644
申请日：1992-07-07
CPC分类号： C07K14/47 , C07K16/18 , C12N15/85 , Y10S530/806
摘要： This invention relates to the identification, characterization, and sequencing of genetic sequences of human secretory granule proteoglycan peptide core protein, recombinant DNA clones directed against this sequence and against the sequence of the antisense RNA, and antibodies which recognize the native human secretory granule proteoglycan.
摘要翻译： 本发明涉及人分泌颗粒蛋白聚糖肽核心蛋白的遗传序列的鉴定，表征和测序，针对该序列的重组DNA克隆和反义RNA的序列，以及识别天然人分泌颗粒蛋白聚糖的抗体。
-
8.发明授权Polynucleotides that encode the human proteoglycan peptide core of the effector cells of the immune response 失效编码免疫应答的效应细胞的人蛋白聚糖肽核心的多核苷酸
公开(公告)号：US5171674A
公开(公告)日：1992-12-15
申请号：US635544
申请日：1991-01-18
摘要： This invention relates to the identification, characterization, and sequencing of genetic sequences of human secretory granule proteoglycan peptide core protein, recombinant DNA clones directed against this sequence and against the sequence of the antisense RNA, and antobodies which recognize the native human secretory granule proteoglycan.
摘要翻译： PCT No.PCT / US89 / 03051 Sec。 371日期1991年1月19日 102（e）1991年1月19日PCT日期为1989年7月13日PCT。本发明涉及人分泌颗粒蛋白聚糖肽核心蛋白的遗传序列的鉴定，表征和测序，针对该序列的重组DNA克隆 反义RNA的序列和识别天然人分泌颗粒蛋白聚糖的独特体。
-
-
-
-
-
-
-
搜索结果
8 条记录 (耗时 0.028 秒)
